L03AA02 - search results

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

neupogen 30 10*6 u inj. sol. s.c./i.v. pre-filled syr.

amgen europe b.v. - filgrastim r-met hug-csf - eq. filgrastim 10000000 u/ml - solution for injection in pre-filled syringe - 30 mio u (0,6 mg/ml) - filgrastim r-met hug-csf - filgrastim

Israel - English - Ministry of Health

accofil 300 mcg0.5 ml

tzamal bio-pharma ltd - filgrastim - solution for injection / infusion - filgrastim 300 mcg / 0.5 ml - filgrastim - accofil is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.the safety and efficacy of accofil are similar in adults and children receiving cytotoxic chemotherapy.accofil is indicated for the mobilisation of peripheral blood progenitor cells (pbpcs).in patients, children or adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (anc) of less or equal to 0.5 x 109 /l, and a history of severe or recurrent infections, long term administration of accofil is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.accofil is indicated for the treatment of persistent neutropenia (anc less than or equal to 1.0 x 109 /l) in patients with advanced hiv infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.

Israel - English - Ministry of Health

accofil 480 mcg0.5 ml

tzamal bio-pharma ltd - filgrastim - solution for injection / infusion - filgrastim 480 mcg / 0.5 ml - filgrastim - accofil is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.the safety and efficacy of accofil are similar in adults and children receiving cytotoxic chemotherapy.accofil is indicated for the mobilisation of peripheral blood progenitor cells (pbpcs).in patients, children or adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (anc) of less or equal to 0.5 x 109 /l, and a history of severe or recurrent infections, long term administration of accofil is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.accofil is indicated for the treatment of persistent neutropenia (anc less than or equal to 1.0 x 109 /l) in patients with advanced hiv infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.